Humanized Mouse Models for Porcine Xenoreactivity Testing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating human immune responses to genetically modified porcine cells for xenotransplantation are inefficient and limited by the use of non-human primate models, which are not fully representative of human immune reactions, leading to prolonged study times and potential misidentification of suitable genetic modifications.
Innovation Solution
Genetically modified porcine cells with knock-out mutations in GGTA, CMAH, β4galNT2, SLA-1, and B2M genes, expressed in porcine liver-derived endothelial cells, exhibit reduced immunoreactivity to human serum and are used for in vitro testing of xenoreactivity, allowing for the identification of suitable genetic modifications for xenotransplantation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-human primate models are used to evaluate human immune responses to genetically modified porcine cells, then preclinical testing can be performed, but the study process becomes prolonged (more than a year) and the model does not fully represent human immune reactions
Solution Approach 1:
The patent uses humanized mouse models that have been genetically engineered to express human immune system components (such as human HLA molecules and human immune cells) to copy human immune responses. This allows the study to maintain reliability in representing human immune reactions while significantly reducing the time required compared to non-human primate models, as the humanized mice can be bred and tested more quickly.
Solution Approach 2:
The patent introduces humanized mouse models as an intermediary system between the genetically modified porcine cells and the human immune system. These mice serve as a bridge that exhibits human-like immune responses to the porcine cells, providing predictive data about human immune reactions without requiring direct human testing or using complex non-human primate models.
2Object-affected harmful factors
If multiple xenoantigens are eliminated through genetic modification of pigs, then human xenoreactivity is reduced, but the complexity of genetic modification and evaluation increases
Solution Approach 1:
The patent segments the complex genetic modification process into manageable components by focusing on specific gene families (such as MHC class I and class II genes) rather than attempting to modify all possible genetic elements. This approach reduces the overall complexity by prioritizing modifications that have the most significant impact on xenoreactivity, while using the humanized mouse model to systematically evaluate each modification's effect.
Data Source
AI summary
Disclosed are genetically modified porcine cells, tissues, organoids, and animals and methods of using the same for transplantation, and testing for xenoreactivity.